The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
2016 · Nature Communications · 1,777 citations
https://doi.org/10.1038/ncomms11479
H
Helena Earl
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
363
Papers
16.9K
Citations
61
h-index
163
i10-index
Helena Earl is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research. The author has an h-index of 61, co-authored 309 publications.
ORCID: 0000-0003-1549-8094Papers by this author
worksOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 · The Lancet · 1,625 citations
https://doi.org/10.1016/s0140-6736(10)60892-6
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
2014 · Annals of Oncology · 779 citations
https://doi.org/10.1093/annonc/mdu191
Multi-omic machine learning predictor of breast cancer therapy response
2021 · Nature · 600 citations
https://doi.org/10.1038/s41586-021-04278-5
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
2015 · Annals of Oncology · 301 citations
https://doi.org/10.1093/annonc/mdv192
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
2019 · The Lancet · 277 citations
https://doi.org/10.1016/s0140-6736(19)30650-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat